SPERO THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.46 USD | +2.10% |
|
+4.29% | -0.68% |
| Mar. 13 | Transcript : Spero Therapeutics, Inc., Q4 2023 Earnings Call, Mar 13, 2024 | |
| Mar. 13 | Spero Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 | CI |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 183.9 | 527.2 | 517.5 | 89.57 | 77.91 | 78.68 | - | - |
| Enterprise Value (EV) 1 | 183.9 | 400.3 | 371.1 | 89.57 | 77.91 | 78.68 | 78.68 | 78.68 |
| P/E ratio | -2.87 x | -5.51 x | -5.5 x | -1.41 x | 3.42 x | -1.56 x | -1.53 x | -2.32 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 10.1 x | 56.5 x | 28.3 x | 1.67 x | 0.75 x | 1.63 x | 1.64 x | 1.4 x |
| EV / Revenue | 10.1 x | 56.5 x | 28.3 x | 1.67 x | 0.75 x | 1.63 x | 1.64 x | 1.4 x |
| EV / EBITDA | -2,944,276 x | -6,728,166 x | -5,926,149 x | - | - | - | - | - |
| EV / FCF | -3,653,934 x | -6,127,763 x | -8,042,348 x | - | - | - | -1,267,047 x | -6,902,072 x |
| FCF Yield | -0% | -0% | -0% | - | - | - | -0% | -0% |
| Price to Book | - | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 19,128 | 27,187 | 32,324 | 51,776 | 52,999 | 53,893 | - | - |
| Reference price 2 | 9.615 | 19.39 | 16.01 | 1.730 | 1.470 | 1.460 | 1.460 | 1.460 |
| Announcement Date | 3/16/20 | 3/11/21 | 3/31/22 | 3/30/23 | 3/13/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 18.15 | 9.33 | 18.26 | 53.51 | 103.8 | 48.23 | 47.83 | 56.25 |
| EBITDA | -62.47 | -78.35 | -87.32 | - | - | - | - | - |
| EBIT 1 | -63.22 | -79.11 | -87.97 | -42.2 | 21.48 | -54.8 | -63.1 | -45.85 |
| Operating Margin | -348.36% | -847.94% | -481.87% | -78.86% | 20.7% | -113.61% | -131.92% | -81.51% |
| Earnings before Tax (EBT) 1 | -60.92 | -78.28 | -89.76 | -46.42 | 25.4 | -51.6 | -62.7 | -7.5 |
| Net income 1 | -60.92 | -78.83 | -89.76 | -46.42 | 22.81 | -53.73 | -62.63 | -45.85 |
| Net margin | -335.73% | -844.9% | -491.65% | -86.74% | 21.98% | -111.4% | -130.94% | -81.51% |
| EPS 2 | -3.350 | -3.520 | -2.910 | -1.230 | 0.4300 | -0.9367 | -0.9533 | -0.6300 |
| Free Cash Flow | -50.33 | -86.03 | -64.35 | - | - | - | -62.1 | -11.4 |
| FCF margin | -277.37% | -922.07% | -352.47% | - | - | - | -129.83% | -20.27% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 3/16/20 | 3/11/21 | 3/31/22 | 3/30/23 | 3/13/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 3.064 | 2.744 | 2.069 | 1.993 | 2.006 | 47.44 | 2.069 | 2.716 | 25.47 | 73.52 | 21.53 | 0.6 | 21.53 | 4.6 | 13 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -22.52 | -27.5 | -30.21 | -14.23 | -11.99 | 25.92 | -14.23 | -12.89 | 3.372 | 50.53 | -2.7 | -24.5 | -4.867 | -22.77 | -6.3 |
| Operating Margin | -735.12% | -1,002.26% | -1,459.98% | -714.05% | -597.51% | 54.64% | -687.63% | -474.59% | 13.24% | 68.73% | -12.54% | -4,083.33% | -22.6% | -494.93% | -48.46% |
| Earnings before Tax (EBT) 1 | -22.52 | -29.24 | -32.83 | -28.68 | -11.68 | 26.77 | -13.27 | -11.91 | -0.994 | 51.58 | -3.225 | -23.28 | -5.375 | -19.72 | - |
| Net income 1 | -22.52 | -29.24 | -32.83 | -28.68 | -11.68 | 26.77 | -13.27 | -11.91 | -3.205 | 51.19 | -2.383 | -24.22 | -4.617 | -22.55 | -6.3 |
| Net margin | -735.02% | -1,065.6% | -1,586.71% | -1,439.14% | -582% | 56.43% | -641.18% | -438.66% | -12.58% | 69.63% | -11.07% | -4,036.11% | -21.44% | -490.22% | -48.46% |
| EPS 2 | -0.7000 | -0.9200 | -1.010 | -0.8700 | -0.3300 | 0.9300 | -0.2500 | -0.2300 | -0.0600 | 0.9600 | -0.0433 | -0.4433 | -0.0833 | -0.3833 | -0.1000 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/10/21 | 3/31/22 | 5/16/22 | 8/10/22 | 11/14/22 | 3/30/23 | 5/11/23 | 8/10/23 | 11/13/23 | 3/13/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | - | 127 | 146 | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow | -50.3 | -86 | -64.3 | - | - | - | -62.1 | -11.4 |
| ROE (net income / shareholders' equity) | -64.1% | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - | - |
| Cash Flow per Share | -2.750 | - | - | - | - | - | - | - |
| Capex 1 | 0.31 | 0.16 | - | - | - | 1 | 1 | 1 |
| Capex / Sales | 1.73% | 1.68% | - | - | - | 2.07% | 2.09% | 1.78% |
| Announcement Date | 3/16/20 | 3/11/21 | 3/31/22 | 3/30/23 | 3/13/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
1.46
USD
Average target price
7.5
USD
Spread / Average Target
+413.70%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -0.68% | 78.68M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- SPRO Stock
- Financials Spero Therapeutics, Inc.
